Mirum Pharmaceuticals

Developing novel therapeutics to treat rare, cholestatic liver diseases

Mirum Pharmaceuticals is developing a novel approach for treating cholestatic liver diseases. The company's lead asset, maralixibat, is a Phase 3-ready investigational oral drug with an established safety profile and strong Phase 2 efficacy data in orphan pediatric indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Frazier EIR Chris Peetz serves as Mirum's President.

Year of Investment

2018

Strategy

Life Sciences

Location

Bay Area, California